Current Drug Targets (CDT) special issue on Covid-19 and Coagulopathy Fibrinolysis in COVID-19: impact on clot lysis and modulation of inflammation
Curr Drug Targets. 2022 Oct 11. doi: 10.2174/1389450123666221011102250. Online ahead of print.ABSTRACTCOVID-19 is a multisystem disease caused by SARS-CoV-2 and is associated with an imbalance between the coagulation and fibrinolytic systems. Systemically, hypercoagulation, hypofibrinolysis and fibrin-clot resistance to fibrinolysis predispose patients to thrombotic and thromboembolic events. In the lungs, the virus triggers alveolar and interstitial fibrin deposition, endothelial dysfunction, and pulmonary intravascular coagulation, all events intrinsically associated with activation of inflammation and organ injury. Addi...
Source: Current Drug Targets - October 12, 2022 Category: Drugs & Pharmacology Authors: Michelle A Sugimoto Luiza O Perucci Luciana P Tavares Mauro M Teixeira Lirl ândia P Sousa Source Type: research

COVID-19 and Thrombosis: Clinical Aspects
Curr Drug Targets. 2022 Oct 5. doi: 10.2174/1389450123666221005092350. Online ahead of print.ABSTRACTIn coronavirus disease 2019 [COVID-19], thrombus formation is related to the pathogenesis of acute respiratory distress syndrome [ARDS] and the progression of clinical symptoms. Severe damage to vascular endothelial cells and the associated cytokine storm after SARS-CoV-2 infection cause thrombogenesis and contribute to the development of more severe and unique thromboses compared to other infectious diseases. Thromboses occur more often in critically ill patients. In addition to pulmonary thromboembolism [PE] and deep vein...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Tetsumei Urano Atsushi Yasumoto Kenji Yokoyama Hisanori Horiuchi Eriko Morishita Yuko Suzuki Source Type: research

Nanotechnology for targeted drug delivery to treat osteoporosis
This article presents the review of various reports on nanocarrier systems and biologics for the treatment of osteoporosis. It aims to provide researchers with a clue for inventing a new drug delivery system with site-specific targeting for the treatment of osteoporosis.PMID:36200208 | DOI:10.2174/1389450123666221004124040 (Source: Current Drug Targets)
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Geeta Aggarwal Source Type: research

Therapeutic potential of HDAC inhibitors in the treatment of cardiac diseases: A short review
Curr Drug Targets. 2022 Oct 3. doi: 10.2174/1389450123666221003094908. Online ahead of print.ABSTRACTProtein acetylation is a reversible central mechanism to control gene expression and cell signaling events. Current evidence suggests that pharmacological inhibitors for protein deacetylation have already been used in various disease conditions. Accumulating reports showed that several compounds that enhance histone acetylation in cells are in both the preclinical and clinical development stages targeting non-communicable diseases, which include cancerous and non-cancerous especially cardiovascular complications. These comp...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Vikas Tiwari Sanjay K Banerjee Source Type: research

COVID-19 and Thrombosis: Clinical Aspects
Curr Drug Targets. 2022 Oct 5. doi: 10.2174/1389450123666221005092350. Online ahead of print.ABSTRACTIn coronavirus disease 2019 [COVID-19], thrombus formation is related to the pathogenesis of acute respiratory distress syndrome [ARDS] and the progression of clinical symptoms. Severe damage to vascular endothelial cells and the associated cytokine storm after SARS-CoV-2 infection cause thrombogenesis and contribute to the development of more severe and unique thromboses compared to other infectious diseases. Thromboses occur more often in critically ill patients. In addition to pulmonary thromboembolism [PE] and deep vein...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Tetsumei Urano Atsushi Yasumoto Kenji Yokoyama Hisanori Horiuchi Eriko Morishita Yuko Suzuki Source Type: research

Nanotechnology for targeted drug delivery to treat osteoporosis
This article presents the review of various reports on nanocarrier systems and biologics for the treatment of osteoporosis. It aims to provide researchers with a clue for inventing a new drug delivery system with site-specific targeting for the treatment of osteoporosis.PMID:36200208 | DOI:10.2174/1389450123666221004124040 (Source: Current Drug Targets)
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Geeta Aggarwal Source Type: research

Therapeutic potential of HDAC inhibitors in the treatment of cardiac diseases: A short review
Curr Drug Targets. 2022 Oct 3. doi: 10.2174/1389450123666221003094908. Online ahead of print.ABSTRACTProtein acetylation is a reversible central mechanism to control gene expression and cell signaling events. Current evidence suggests that pharmacological inhibitors for protein deacetylation have already been used in various disease conditions. Accumulating reports showed that several compounds that enhance histone acetylation in cells are in both the preclinical and clinical development stages targeting non-communicable diseases, which include cancerous and non-cancerous especially cardiovascular complications. These comp...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Vikas Tiwari Sanjay K Banerjee Source Type: research

COVID-19 and Thrombosis: Clinical Aspects
Curr Drug Targets. 2022 Oct 5. doi: 10.2174/1389450123666221005092350. Online ahead of print.ABSTRACTIn coronavirus disease 2019 [COVID-19], thrombus formation is related to the pathogenesis of acute respiratory distress syndrome [ARDS] and the progression of clinical symptoms. Severe damage to vascular endothelial cells and the associated cytokine storm after SARS-CoV-2 infection cause thrombogenesis and contribute to the development of more severe and unique thromboses compared to other infectious diseases. Thromboses occur more often in critically ill patients. In addition to pulmonary thromboembolism [PE] and deep vein...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Tetsumei Urano Atsushi Yasumoto Kenji Yokoyama Hisanori Horiuchi Eriko Morishita Yuko Suzuki Source Type: research

Nanotechnology for targeted drug delivery to treat osteoporosis
This article presents the review of various reports on nanocarrier systems and biologics for the treatment of osteoporosis. It aims to provide researchers with a clue for inventing a new drug delivery system with site-specific targeting for the treatment of osteoporosis.PMID:36200208 | DOI:10.2174/1389450123666221004124040 (Source: Current Drug Targets)
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Geeta Aggarwal Source Type: research

Therapeutic potential of HDAC inhibitors in the treatment of cardiac diseases: A short review
Curr Drug Targets. 2022 Oct 3. doi: 10.2174/1389450123666221003094908. Online ahead of print.ABSTRACTProtein acetylation is a reversible central mechanism to control gene expression and cell signaling events. Current evidence suggests that pharmacological inhibitors for protein deacetylation have already been used in various disease conditions. Accumulating reports showed that several compounds that enhance histone acetylation in cells are in both the preclinical and clinical development stages targeting non-communicable diseases, which include cancerous and non-cancerous especially cardiovascular complications. These comp...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Vikas Tiwari Sanjay K Banerjee Source Type: research

COVID-19 and Thrombosis: Clinical Aspects
Curr Drug Targets. 2022 Oct 5. doi: 10.2174/1389450123666221005092350. Online ahead of print.ABSTRACTIn coronavirus disease 2019 [COVID-19], thrombus formation is related to the pathogenesis of acute respiratory distress syndrome [ARDS] and the progression of clinical symptoms. Severe damage to vascular endothelial cells and the associated cytokine storm after SARS-CoV-2 infection cause thrombogenesis and contribute to the development of more severe and unique thromboses compared to other infectious diseases. Thromboses occur more often in critically ill patients. In addition to pulmonary thromboembolism [PE] and deep vein...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Tetsumei Urano Atsushi Yasumoto Kenji Yokoyama Hisanori Horiuchi Eriko Morishita Yuko Suzuki Source Type: research

Nanotechnology for targeted drug delivery to treat osteoporosis
This article presents the review of various reports on nanocarrier systems and biologics for the treatment of osteoporosis. It aims to provide researchers with a clue for inventing a new drug delivery system with site-specific targeting for the treatment of osteoporosis.PMID:36200208 | DOI:10.2174/1389450123666221004124040 (Source: Current Drug Targets)
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Geeta Aggarwal Source Type: research

Therapeutic potential of HDAC inhibitors in the treatment of cardiac diseases: A short review
Curr Drug Targets. 2022 Oct 3. doi: 10.2174/1389450123666221003094908. Online ahead of print.ABSTRACTProtein acetylation is a reversible central mechanism to control gene expression and cell signaling events. Current evidence suggests that pharmacological inhibitors for protein deacetylation have already been used in various disease conditions. Accumulating reports showed that several compounds that enhance histone acetylation in cells are in both the preclinical and clinical development stages targeting non-communicable diseases, which include cancerous and non-cancerous especially cardiovascular complications. These comp...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Vikas Tiwari Sanjay K Banerjee Source Type: research

COVID-19 and Thrombosis: Clinical Aspects
Curr Drug Targets. 2022 Oct 5. doi: 10.2174/1389450123666221005092350. Online ahead of print.ABSTRACTIn coronavirus disease 2019 [COVID-19], thrombus formation is related to the pathogenesis of acute respiratory distress syndrome [ARDS] and the progression of clinical symptoms. Severe damage to vascular endothelial cells and the associated cytokine storm after SARS-CoV-2 infection cause thrombogenesis and contribute to the development of more severe and unique thromboses compared to other infectious diseases. Thromboses occur more often in critically ill patients. In addition to pulmonary thromboembolism [PE] and deep vein...
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Tetsumei Urano Atsushi Yasumoto Kenji Yokoyama Hisanori Horiuchi Eriko Morishita Yuko Suzuki Source Type: research

Nanotechnology for targeted drug delivery to treat osteoporosis
This article presents the review of various reports on nanocarrier systems and biologics for the treatment of osteoporosis. It aims to provide researchers with a clue for inventing a new drug delivery system with site-specific targeting for the treatment of osteoporosis.PMID:36200208 | DOI:10.2174/1389450123666221004124040 (Source: Current Drug Targets)
Source: Current Drug Targets - October 6, 2022 Category: Drugs & Pharmacology Authors: Malkiet Kaur Manju Nagpal Geeta Aggarwal Source Type: research